The CEPI-funded Nipah vaccine candidate is a live attenuated measles vector-based vaccine containing the Nipah-virus G gene (Malaysia strain). The recombinant vaccine candidate was developed at The Institute of Medical Science, University of Tokyo, and has shown to induce humoral and cellular responses in a preclinical study. In addition, the vaccine protected against lethal nipah virus infection in a hamster and non-human primate model. Process development and manufacturing is under development at Batavia Biosciences.